Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

OncoSec Medical stock

ONCS
US68234L3069
A2PKW3

Price

0.00
Today +/-
+0
Today %
+0 %

OncoSec Medical stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the OncoSec Medical stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the OncoSec Medical stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the OncoSec Medical stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze OncoSec Medical's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

OncoSec Medical Stock Price History

DateOncoSec Medical Price
8/23/20230.00 undefined
8/22/20230.00 undefined

OncoSec Medical Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into OncoSec Medical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by OncoSec Medical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects OncoSec Medical’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of OncoSec Medical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into OncoSec Medical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing OncoSec Medical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on OncoSec Medical’s growth potential.

OncoSec Medical Revenue, EBIT and net profit per share

DateOncoSec Medical RevenueOncoSec Medical EBITOncoSec Medical Net Income
2026e9.23 M undefined-34.68 M undefined-27.15 M undefined
2025e8.79 M undefined-34.63 M undefined-22.88 M undefined
2024e8.54 M undefined-35.26 M undefined-19.67 M undefined
2023e0 undefined-37.74 M undefined-95.16 M undefined
20220 undefined-37.01 M undefined-34.18 M undefined
20210 undefined-48.38 M undefined-45.17 M undefined
20200 undefined-43.41 M undefined-42.25 M undefined
20190 undefined-30.42 M undefined-30.28 M undefined
20180 undefined-36.1 M undefined-39.14 M undefined
20170 undefined-21.45 M undefined-21.45 M undefined
20160 undefined-26.89 M undefined-26.89 M undefined
20150 undefined-21.24 M undefined-21.24 M undefined
20140 undefined-11.95 M undefined-12.01 M undefined
20130 undefined-7.06 M undefined-7.15 M undefined
20120 undefined-5.53 M undefined-2.36 M undefined
20110 undefined-1.7 M undefined-3.76 M undefined
20100 undefined-30,000 undefined-40,000 undefined
20090 undefined-30,000 undefined-30,000 undefined
20080 undefined-10,000 undefined-10,000 undefined

OncoSec Medical Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e
0000000000000000889
------------------12.50
-------------------
0000000000000000000
000-3-2-7-12-21-26-21-39-30-42-45-34-95-19-22-27
-----33.33250.0071.4375.0023.81-19.2385.71-23.0840.007.14-24.44179.41-80.0015.7922.73
0.340.340.340.320.340.530.951.271.652.024.017.050.751.51.790000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The OncoSec Medical Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the OncoSec Medical is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200820092010201120122013201420152016201720182019202020212022
                             
0.040.0102.465.144.9737.8532.0428.7511.4426.9825.1520.3545.9512.3
000000000000000
000000000000000
000000000000000
00.0100.450.350.20.461.530.671.071.643.362.473.232.93
0.040.0202.915.495.1738.3133.5729.4212.5128.6228.5122.8249.1815.23
0000.060.080.150.581.812.82.411.271.036.766.375.64
000000000000000
000000000000000
0002.721.861.160.460000000.450.38
000000000000000
0100003030210190310360350319.06273.52623.24
00.0102.781.941.341.072.022.992.721.631.387.087.16.65
0.040.0305.697.436.5139.3835.5932.4115.2330.2529.8929.956.2821.88
                             
001010101020203001002.313.923.94
0.050.050.041.035.5911.4756.0871.5788.2393.87145.74177.66214.79286.34288.23
-0.01-0.04-0.08-3.4-1.18-6.74-18.04-38.9-60.21-83.17-122.81-153.55-200.9-248.19-282.37
0000000000-20170-19.5-79.11247.21
000000000000000
0.040.01-0.03-2.364.424.7438.0632.6928.0510.722.9224.2813.8738.086.12
00.010.020.370.380.731.242.363.223.284.780000
0000.070.220.060.090.530.240.110.234.268.616.65.58
00.010.016.11.420.9800000.840.630.090.130.12
0000000000080000
0000000000000.971.230.94
00.020.036.542.021.771.332.893.463.395.854.979.687.966.63
000000000000480.5500
000000000000000
0001.50.980000.891.141.470.645.8710.249.13
0001.50.980000.891.141.470.646.3510.249.13
00.020.038.0431.771.332.894.354.537.325.6116.0318.215.76
0.040.0305.687.426.5139.3935.5832.415.2330.2429.8929.956.2821.88
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of OncoSec Medical provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand OncoSec Medical's financial health and stability.

Assets

OncoSec Medical's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that OncoSec Medical must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of OncoSec Medical after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into OncoSec Medical's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200820092010201120122013201420152016201720182019202020212022
000-3-2-7-12-21-26-21-39-30-42-45-34
000000000000000
000000000000000
00000000202-33-2-1
0001-201264134553
000000000000000
000000000000000
000-1-4-5-8-17-17-17-23-29-33-41-32
0000000-1-1000000
0000000-1-10-2323000
0000000000-2323000
000000000000000
00000-1-10000000-1
0004774514170422829680
000465421316038272868-1
-------1.00-1.00-1.00--3.00-1.00-2.00--
000000000000000
00022032-5-3-17-721-425-33
-0.01-0.03-0.01-1.62-4.27-5.64-9.49-19.08-19.36-17.36-23.29-29.01-33.15-42.59-32.38
000000000000000

OncoSec Medical stock margins

The OncoSec Medical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of OncoSec Medical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for OncoSec Medical.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the OncoSec Medical's sales revenue. A higher gross margin percentage indicates that the OncoSec Medical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the OncoSec Medical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the OncoSec Medical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the OncoSec Medical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the OncoSec Medical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the OncoSec Medical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

OncoSec Medical Margin History

OncoSec Medical Gross marginOncoSec Medical Profit marginOncoSec Medical EBIT marginOncoSec Medical Profit margin
2026e0 %-375.63 %-294.02 %
2025e0 %-393.77 %-260.23 %
2024e0 %-412.79 %-230.32 %
2023e0 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %

OncoSec Medical Stock Sales Revenue, EBIT, Earnings per Share

The OncoSec Medical earnings per share therefore indicates how much revenue OncoSec Medical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue OncoSec Medical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates OncoSec Medical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of OncoSec Medical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating OncoSec Medical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

OncoSec Medical Revenue, EBIT and net profit per share

DateOncoSec Medical Sales per ShareOncoSec Medical EBIT per shareOncoSec Medical Earnings per Share
2026e0.23 undefined0 undefined-0.69 undefined
2025e0.22 undefined0 undefined-0.58 undefined
2024e0.22 undefined0 undefined-0.5 undefined
2023e0 undefined0 undefined-2.42 undefined
20220 undefined-20.72 undefined-19.13 undefined
20210 undefined-32.35 undefined-30.2 undefined
20200 undefined-57.76 undefined-56.23 undefined
20190 undefined-4.31 undefined-4.3 undefined
20180 undefined-9 undefined-9.76 undefined
20170 undefined-10.62 undefined-10.62 undefined
20160 undefined-16.3 undefined-16.3 undefined
20150 undefined-16.72 undefined-16.72 undefined
20140 undefined-12.58 undefined-12.64 undefined
20130 undefined-13.32 undefined-13.49 undefined
20120 undefined-16.26 undefined-6.94 undefined
20110 undefined-5.31 undefined-11.75 undefined
20100 undefined-0.09 undefined-0.12 undefined
20090 undefined-0.09 undefined-0.09 undefined
20080 undefined-0.03 undefined-0.03 undefined

OncoSec Medical business model

OncoSec Medical Inc is a US-based company specializing in the development of cancer treatment methods through immunotherapy. The company was founded in 2011 and is headquartered in San Diego, California. The history of OncoSec Medical Inc began with the idea of improving tumor treatments through electroporation. Electroporation is a process that uses electric pulses to increase the permeability of cell membranes. This facilitates the exchange of molecules and the uptake of drugs, which is used in the treatment of cancer cells. The business model of OncoSec Medical Inc is based on the development and commercialization of immunotherapies to combat cancer. Electroporation is used to locally infect tumor lesions with reactivated T-cells and other immune cells to generate an immune response. OncoSec Medical Inc has developed a proprietary platform called ImmunoPulse, which combines electroporation and immunotherapy. The company is divided into various divisions, including research and development, clinical trials, manufacturing, and distribution. Research and development focus on identifying potential immunotherapies and testing drug candidates. Clinical trials are designed to confirm the effectiveness and safety of therapies through clinical testing. Manufacturing involves the production of drug candidates and clinical preparations in accordance with Good Manufacturing Practices (GMPs). Distribution includes the sale and marketing of approved therapies to patients and healthcare providers. OncoSec Medical Inc offers a variety of immunotherapies for the treatment of various types of cancer. This includes ImmunoPulse IL-12 therapy, which is used to treat metastatic melanoma. The company is also working on several other therapies, including the Verapamil-Plus-IL-2 protocol for the treatment of breast and prostate cancer. In summary, OncoSec Medical Inc is an emerging biotechnology company specializing in the development and commercialization of immunotherapies to combat cancer. Through its proprietary ImmunoPulse platform and extensive research and development, the company strives to provide effective and safe treatment options for cancer patients, fully harnessing the potential of immunotherapy. OncoSec Medical is one of the most popular companies on Eulerpool.com.

OncoSec Medical SWOT Analysis

Strengths

1. Strong Intellectual Property (IP) Portfolio: OncoSec Medical Inc possesses a robust IP portfolio that includes patents and trademarks, providing a competitive advantage in the field of immunotherapy.

2. Innovative Technology: The company's proprietary technology, called ImmunoPulse®, enables the delivery of DNA-based immunotherapies directly into tumors, offering a potentially effective and safer treatment option.

3. Promising Clinical Pipeline: OncoSec has a diverse and promising clinical pipeline, with multiple ongoing trials in various stages for different cancer indications, indicating potential future revenue streams.

Weaknesses

1. Limited Market Presence: OncoSec Medical Inc faces strong competition from well-established pharmaceutical and biotechnology companies in the rapidly evolving immunotherapy market, making it challenging to gain market share.

2. High Research and Development (R&D) Expenditure: The company's focus on innovation and clinical development necessitates significant R&D spending, which may strain finances in the absence of substantial revenues.

3. Regulatory Risks: As an emerging biotech company, OncoSec is subject to regulatory scrutiny and faces risks associated with obtaining necessary approvals for its products, which could delay commercialization timelines.

Opportunities

1. Growing Demand for Immunotherapies: Increasing prevalence of cancer and the need for more effective treatment options present significant market opportunities, especially in the field of immunotherapy, where OncoSec operates.

2. Collaborations and Partnerships: OncoSec can explore collaborations and partnerships with larger pharmaceutical companies to expand its market reach, leverage existing distribution channels, and gain access to additional resources.

3. Expansion into International Markets: As the company continues to demonstrate the efficacy of its products, expanding into international markets can provide additional revenue streams and tap into regions with substantial unmet medical needs.

Threats

1. Competitive Landscape: The immunotherapy market is highly competitive, with established players and other emerging biotechnology companies constantly introducing new and advanced therapies, posing a threat to OncoSec's market position.

2. Stringent Regulations: Changing regulations and compliance requirements in the healthcare and biotechnology sectors can significantly impact OncoSec's operations, increasing costs and causing delays.

3. Technological Advancements: Rapid advancements in technology may render OncoSec's current technology obsolete or less effective, necessitating continuous innovation and potential investments to stay competitive.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

OncoSec Medical Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

OncoSec Medical historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

OncoSec Medical shares outstanding

The number of shares was OncoSec Medical in 2024 — This indicates how many shares 1.787 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue OncoSec Medical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates OncoSec Medical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of OncoSec Medical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating OncoSec Medical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

OncoSec Medical stock splits

In OncoSec Medical's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for OncoSec Medical.

OncoSec Medical shareholders

%
Name
Stocks
Change
Date
1.93964 % Grand Pharmaceutical Group Ltd763,54901/25/2023
0.38793 % Sirtex Medical US Holdings Inc152,71101/25/2023
0.08497 % Two Sigma Investments, LP33,45033,45012/31/2022
0.06398 % State Street Global Advisors (US)25,18723,19912/31/2022
0.06142 % Renaissance Technologies LLC24,17921,11512/31/2022
0.05284 % Salzhauer Michael20,7997,33212/31/2022
0.04428 % BNY Mellon Asset Management17,433212/31/2022
0.03651 % Highland Capital Management, L.P.14,37414,3749/30/2021
0.03299 % Virtu Americas LLC12,98712,44412/31/2022
0.03175 % Geode Capital Management, L.L.C.12,4983512/31/2022
1
2
3
4
5
...
8

OncoSec Medical Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Cryosite Stock
Cryosite
SupplierCustomer0,940,55-0,72-0,30-0,48
Merck & Co Stock
Merck & Co
SupplierCustomer0,79-0,32-0,56-0,49-0,40-0,50
Baxter Intl Stock
Baxter Intl
SupplierCustomer0,26-0,190,570,11-0,050,01
Alpha Holdings KR Stock
Alpha Holdings KR
SupplierCustomer0,200,670,280,260,880,91
SGS Stock
SGS
SupplierCustomer-0,310,170,350,130,39-0,25
Inovio Pharmaceuticals Stock
Inovio Pharmaceuticals
SupplierCustomer-0,330,710,880,620,880,52
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group
SupplierCustomer-0,620,530,670,390,720,39
1

Most common questions regarding OncoSec Medical

What values and corporate philosophy does OncoSec Medical represent?

OncoSec Medical Inc represents values of innovation, commitment, and patient-focused care. The company philosophy revolves around advancing novel oncology treatments through its proprietary ImmunoPulse® platform technology. With a strong focus on delivering effective and safe therapies, OncoSec Medical Inc prioritizes patient well-being and aims to improve cancer treatment outcomes. Through strategic collaborations and a dedicated research and development approach, the company strives to redefine the way cancer is treated, offering hope to patients worldwide. OncoSec Medical Inc's commitment to transforming cancer therapy reinforces its position as a leading player in the oncology sector.

In which countries and regions is OncoSec Medical primarily present?

OncoSec Medical Inc is primarily present in the United States.

What significant milestones has the company OncoSec Medical achieved?

OncoSec Medical Inc has achieved several significant milestones in the field of cancer immunotherapy. The company successfully completed the Phase II OMS Study, demonstrating positive clinical results in patients with metastatic melanoma. They also received FDA Breakthrough Therapy Designation for their lead product candidate, TAVO, which facilitates the local delivery of DNA-based immunotherapies. OncoSec Medical Inc further expanded its pipeline through strategic collaborations with Merck and Roswell Park Comprehensive Cancer Center. The company's dedication to advancing innovative therapies and improving patient outcomes has positioned OncoSec Medical Inc as a key player in the immunotherapy industry.

What is the history and background of the company OncoSec Medical?

OncoSec Medical Inc. is a biotechnology company focused on developing innovative immunotherapies to combat cancer. Established in 2011, the company has grown rapidly due to its commitment to pioneering research and development. OncoSec's expertise lies in its proprietary technology platform, ImmunoPulse®, which harnesses the power of electroporation to enhance the delivery of DNA-based immunotherapies directly into the tumor. By leveraging this cutting-edge approach, OncoSec aims to revolutionize cancer treatment and improve patient outcomes. With a strong emphasis on clinical trials and strategic partnerships, OncoSec continues to make significant strides in the field of oncology.

Who are the main competitors of OncoSec Medical in the market?

The main competitors of OncoSec Medical Inc in the market include companies like Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis AG, Genentech, Inc., and Amgen Inc. These pharmaceutical giants operate in the same healthcare sector, specializing in oncology and immunotherapy. While OncoSec Medical Inc focuses on developing innovative and effective cancer treatments, it faces competition from these established players who also strive to provide cutting-edge advancements in the field.

In which industries is OncoSec Medical primarily active?

OncoSec Medical Inc is primarily active in the biotechnology and healthcare industries.

What is the business model of OncoSec Medical?

The business model of OncoSec Medical Inc focuses on developing innovative immunotherapy treatments for cancer patients. By leveraging its proprietary technology, OncoSec aims to empower the body's immune system to effectively target and destroy tumor cells. The company's comprehensive approach includes utilizing electroporation to enhance the delivery of DNA-based immunotherapies directly into the tumor. By doing so, OncoSec seeks to provide patients with potential solutions that are both safe and effective in combating various types of cancer. Through ongoing research and development, OncoSec Medical Inc strives to revolutionize cancer treatment and improve patient outcomes.

What is the P/E ratio of OncoSec Medical 2025?

The OncoSec Medical P/E ratio is -0.

What is the P/S ratio of OncoSec Medical 2025?

The OncoSec Medical P/S ratio is 0.

What is the Quality Investing of OncoSec Medical?

The Quality Investing for OncoSec Medical is 4/10.

What is the revenue of OncoSec Medical 2025?

The expected OncoSec Medical revenue is 8.79 M USD.

How high is the profit of OncoSec Medical 2025?

The expected OncoSec Medical profit is -22.88 M USD.

What is the business model of OncoSec Medical

OncoSec Medical Inc is a leading company in the field of immuno-oncology therapy. Based in San Diego, California, the company aims to develop a novel class of cancer treatments that specifically activate the patient's own immune system, potentially leading to healing effects. OncoSec Medical's core business involves the research, development, and commercialization of immune-dominant therapy approaches based on the innovation of electroporation technology. This technology uses electrical pulses to enhance the delivery of therapeutic agents into tumor cells, resulting in more targeted and effective therapeutic outcomes. The flagship product of OncoSec Medical is the ImmunoPulse System, a groundbreaking therapy that synergistically combines electroporation and immunity to generate coordinated anti-tumoral immune responses. The system provides a fast, highly effective, and safe treatment option that has a positive impact on the survival of patients with advanced skin cancer. ImmunoPulse is capable of treating both primary and metastatic tumors and has the potential to be used in many other cancer types. In addition to ImmunoPulse, OncoSec Medical also offers other innovative therapy approaches such as the DNA plasmid vector system. This system aims to inhibit the rheostat function of tumor cells in the growth factor signaling pathway, thereby inhibiting tumor growth. OncoSec Medical also has a pipeline of products, including OMS-776, an agonist of Toll-like receptors that is capable of enhancing the immune response to the tumor microenvironment, and OMS-905, an immunosuppressive drug that improves T-cell regulation in cancer patients. OncoSec Medical is an innovative company that collaborates closely with leading scientists and research partners to develop the next generation of cancer treatments. The company is committed to revolutionizing the way cancer is treated and improving the lives of patients worldwide. With its unique approach and strong pipeline of products, OncoSec Medical is well positioned to meet the evolving needs of patients and providers in the field of cancer treatment. In summary, OncoSec Medical's business model consists of a combination of research, development, and commercialization of immuno-oncology therapies based on innovative electroporation technology. The company offers a wide range of products, including the ImmunoPulse system, DNA plasmid vectors, and drug candidates such as OMS-776 and OMS-905. With its strong pipeline of products and vision to revolutionize cancer treatment, OncoSec Medical is an exciting and promising company that plays a prominent role in cancer research and treatment.

What is the OncoSec Medical dividend?

OncoSec Medical pays a dividend of 0 USD distributed over payouts per year.

How often does OncoSec Medical pay dividends?

The dividend cannot currently be calculated for OncoSec Medical or the company does not pay out a dividend.

What is the OncoSec Medical ISIN?

The ISIN of OncoSec Medical is US68234L3069.

What is the OncoSec Medical WKN?

The WKN of OncoSec Medical is A2PKW3.

What is the OncoSec Medical ticker?

The ticker of OncoSec Medical is ONCS.

How much dividend does OncoSec Medical pay?

Over the past 12 months, OncoSec Medical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, OncoSec Medical is expected to pay a dividend of 0 USD.

What is the dividend yield of OncoSec Medical?

The current dividend yield of OncoSec Medical is .

When does OncoSec Medical pay dividends?

OncoSec Medical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of OncoSec Medical?

OncoSec Medical paid dividends every year for the past 0 years.

What is the dividend of OncoSec Medical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is OncoSec Medical located?

OncoSec Medical is assigned to the 'Health' sector.

Wann musste ich die Aktien von OncoSec Medical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of OncoSec Medical from 2/16/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/16/2025.

When did OncoSec Medical pay the last dividend?

The last dividend was paid out on 2/16/2025.

What was the dividend of OncoSec Medical in the year 2024?

In the year 2024, OncoSec Medical distributed 0 USD as dividends.

In which currency does OncoSec Medical pay out the dividend?

The dividends of OncoSec Medical are distributed in USD.

All fundamentals about OncoSec Medical

Our stock analysis for OncoSec Medical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OncoSec Medical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.